Zhengye Biotechnology Holding Limited (ZYBT) Financial Statements

Income statement

Metric	2025	2024	2023	2022
Revenue
Total Revenue	116.4M	186.4M	211.7M	260.3M
Cost of Revenue	92.5M	95.1M	81.8M	106.8M
Gross Profit	23.9M	91.3M	129.9M	153.5M
Operating Expenses
R&D Expense	18.0M	12.8M	11.9M	13.4M
SG&A Expense	74.9M	63.8M	66.6M	63.6M
General & Admin Expense	31.0M	22.6M	25.9M	29.0M
Selling & Marketing Expense	43.9M	41.3M	40.7M	34.6M
Other Expenses	(814.0K)	(1.8M)	6.3M	10.7M
Total Operating Expenses	92.1M	74.9M	84.9M	87.7M
Cost and Expenses	184.6M	169.9M	166.7M	194.4M
Operating Income (EBIT)	(68.3M)	16.4M	45.0M	65.8M
Non-Operating
Interest Income	96.0K	231.0K	312.0K	114.0K
Interest Expense	3.4M	4.0M	4.4M	2.8M
Net Interest Income	(3.3M)	(3.8M)	(4.1M)	(2.7M)
Other Non-Op Income/Expense	(3.6M)	(2.0M)	(1.2M)	(1.9M)
Non-Operating Income (excl Interest)	219.0K	(2.0M)	(3.2M)	(919.0K)
EBT (Pre-Tax Income)	(71.9M)	14.4M	43.8M	63.9M
Income Tax Expense	11.1M	924.0K	6.3M	8.2M
Bottom Line
Net Income	(69.8M)	11.3M	31.5M	46.7M
Earnings from Cont. Ops	(83.0M)	13.5M	37.5M	55.7M
Earnings from Discont. Ops	—	—	—	—
Bottom Line Net Income	(69.8M)	11.3M	31.5M	46.7M
Per Share
Basic EPS	($1.40)	$0.24	$0.69	$1.02
Diluted EPS	($1.40)	$0.24	$0.67	$0.99
Revenue Per Share	$2.46	$3.95	$4.63	$5.70
Shares
Basic Shares Outstanding	47.3M	47.2M	45.7M	45.7M
Diluted Shares Outstanding	47.3M	47.2M	47.2M	47.2M
Profitability Metrics
EBITDA	(42.5M)	42.6M	72.1M	85.6M
D&A	26.0M	24.2M	23.9M	18.8M
EBIT	(68.5M)	18.4M	48.2M	66.8M

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025